Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1633-1640

  Perissinotti, Anthony J ^a,b   Reeves, David J ^c,d,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d ST VINCENT HOSPITAL   (United States)

^e BUTLER UNIVERSITY   (United States)

Author keywords

Intrathecal; Leptomeningeal carcinomatosis; Monoclonal antibody; Rituximab; Trastuzumab

Indexed keywords

CIMETIDINE; CYTARABINE; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAMOTIDINE; HYDROCORTISONE; METHOTREXATE; PARACETAMOL; PREDNISONE; RITUXIMAB; THIOTEPA; TRASTUZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARACHNOIDITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; BACKACHE; BLOOD BRAIN BARRIER; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID; CHILL; CLINICAL TRIAL; DIPLOPIA; DISORIENTATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; LARGE CELL LYMPHOMA; LOADING DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MEDLINE; MEDULLOBLASTOMA; NAUSEA; NEUROPATHIC PAIN; NONHODGKIN LYMPHOMA; NONHUMAN; PARAPLEGIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TACHYPNEA; THERAPY EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; VOMITING; WEAKNESS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INJECTIONS, SPINAL; MENINGEAL CARCINOMATOSIS;

EID: 77957681665     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P197     Document Type: Review

References (36)

1. National Comprehensive Cancer Network. Central nervous system cancers. v. 3. 2009. www.nccn.org/professionals/physician-gls/PDF/cns.pdf (accessed 2010 Feb 1).
2. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-19. DOI 10.1053/crv.1999.0119
3. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9. DOI 10.1158/1078-0432.CCR-08-1080
4. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9. DOI 10.1200/JCO.2007.3588
5. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86. DOI 10.1200/JCO.2008.19.8481
6. Pestalozzi BC, Brignoli S. Trastuzumab in CSF (letter). J Clin Oncol 2000;18:2349-51.
7. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-8. DOI 10.1097/01.cad. 0000236313.50833.ee
8. Grossi PM, Ochiai H, Archer GE, et al. Efficacy of intrathecal microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003;9:5514-20.
9. Braen AP, Perron J, Tellier P, Catala AR, Kolaitis G, Geng W. A 4-week intrathecal toxicity and pharamcokinetic study with trastuzumab in cynomolgus monkeys. Int J Toxicol 2010;29:259-67. DOI 10.1177/1091581810361527
10. Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastastic breast cancer: a case report. Anticancer Drugs 2008;19:832-6. DOI 10.1097/CAD.0b013e32830b58b0
11. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis (letter). Clin Breast Cancer 2001;2:235.
12. Colozza M, Minenza E, Gori S, et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009;63:1157-9. DOI 10.1007/s00280-008-0859-7
13. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastastic breast cancer. Oncol Rep 2006;15:1373-7.
14. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer (letter). Ann Oncol 2009;20:792-5. DOI 10.1093/annonc/mdp019
15. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer (letter). Ann Oncol 2008;19:1978-80. DOI 10.1093/annonc/mdn654
16. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006;7:778-80. DOI 10.1016/SI1470-2045(06)70864-6
17. Shojima K, Suzuki E, Saito K, et al. Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastastic breast cancer (abstract 1138). J Clin Oncol 2008;26:75S.
18. Allison DL, Glantz M, Werner TL, Kirkegaard SL, Murdock K, Jensen R. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors (abstract 2066). J Clin Oncol 2009;27:15S.
19. Pegram M, Hsu S Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
20. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129-33. DOI 10.1093/annonc/mdh013
21. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
22. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-8. DOI 10.1182/blood-2002-06-1636
23. Villela L, Garcia M, Caballero R, Borbolla-Escoboza JR, Bolanos-Meade J. Rapid complete response using intrathecal rituzimab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs 2008;19:917-20. DOI 10.1097/CAD.0b013e32830cebc1
24. Antonini G, Cox MC, Montefusco E, et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007;81:197-9. DOI 10.1007/s11060-006-9217-y
25. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008;50:886-8. DOI 10.1002/pbc.21297
26. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002;59:213-6. DOI 10.1023/A:1019999830455
27. Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen PM, Hsiao LT. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab (letter). Leuk Lymphoma 2008;49:2018-21. DOI 10.1080/10428190802311375
28. Akyuz C, Burca Aydin G, Cila A, et al. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child (letter). Leuk Lymphoma 2007;48:1253-5. DOI 10.1080/10428190601142831
29. Hong SJ, Kim JS, Chang JH, et al. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high dose chemotherapy with autologous stem cell rescue. Yonsei Med J 2009;50:280-3. DOI 10.3349/ymj.2009.50.2.280
30. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with anti-CD20 antibody rituximab (letter). Haematologica 2004;89:753-4.
31. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, Chapa-Rodriguez A, Gomez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukemia relapsed to the CNS and resistant to conventional therapy (letter). Br J Haematol 2008;144:794-805. DOI 10.1111/j.1365-2141.2008.07497.x
32. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350-6. DOI 10.1200/JCO.2006.09.7311
33. Siderov J. Care with intrathecal trastuzumab (letter). Lancet Oncol 2006;7:888.
34. Electronic medicines compendium. http://emc.medicines.org.uk/emc/ industry/default.asp?page=displaydoc.asp&documentid=3567 (accessed 2010 Jun 9).
35. Blaney SM, Poplock DG, Godwin K, McCully CL, Murphy R, Balis FM. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol 1995;13:177-9.
36. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161-6.